Osteoactivin (also named GPNMB and DC-HIL) is a 125 kDa, intracellular glycoprotein that is associated with cell endosomal/lysosomal compartments (1, 2). Mouse osteoactivin is synthesized as a type I, transmembrane, 574 amino acid (aa) precursor that contains a 22 aa signal sequence, a 478 aa luminal/extracellular domain, a 23 aa transmembrane segment and a 51 aa cytoplasmic tail. The luminal region contains an N-terminal heparin-binding motif, multiple glycosylation sites, an RGD motif and a 130 aa PKD domain. The intracellular tail also has an RGD motif, plus an ITAM (Y-x-x-I) and lysosomal targeting (L-L) motif. The extracellular/luminal region is 89% and 74% aa identical to the equivalent regions in rat and human, respectively. Cells known to express osteoactivin include osteoblasts, dendritic cells, and melanocytes, plus fetal chondrocytes and stratum basale keratinocytes (2, 3). Osteoactivin is reported to bind to heparan sulfate-proteoglycan, possibly on the surface of fibroblasts and endothelial cells (2). It may also interact with integrins.
Mouse Osteoactivin/GPNMB Antibody (297310)
R&D Systems | Catalog # MAB2330
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Lys23-Asn502
Accession # NP_444340
Specificity
Clonality
Host
Isotype
Scientific Data Images for Mouse Osteoactivin/GPNMB Antibody (297310)
Detection of Osteoactivin/GPNMB by Immunohistochemistry
Features of DBA-g+ and DBA mice.(A) Expression of Gpnmb is observed in DBA-g+ but not DBA mice following a single injection of CCl4. However, (B) sequential changes in serum ALT levels and the degree of liver injury are not affected by the lack of Gpnmb-positive macrophages (original magnification, x100). Conversely, (C) the areas of fibrosis and (D) the number of alpha -SMA-positive cells are significantly decreased in the liver tissues of DBA mice compared to DBA-g+ mice (original magnification, x200). Additionally, (E) although lack of Gpnmb-positive macrophages does not affect expression of TGF-beta or Col1 alpha 1, expression of MMP-9, MMP-13, and TIMP-1 are significantly decreased in mice lacking Gpnmb expression at six or eight days after single injection of CCl4. Values are mean ± SEM (n = 4). * P < 0.05 (Mann-Whitney U test). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/26599547), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Osteoactivin/GPNMB by Western Blot
Features of DBA-g+ and DBA mice.(A) Expression of Gpnmb is observed in DBA-g+ but not DBA mice following a single injection of CCl4. However, (B) sequential changes in serum ALT levels and the degree of liver injury are not affected by the lack of Gpnmb-positive macrophages (original magnification, x100). Conversely, (C) the areas of fibrosis and (D) the number of alpha -SMA-positive cells are significantly decreased in the liver tissues of DBA mice compared to DBA-g+ mice (original magnification, x200). Additionally, (E) although lack of Gpnmb-positive macrophages does not affect expression of TGF-beta or Col1 alpha 1, expression of MMP-9, MMP-13, and TIMP-1 are significantly decreased in mice lacking Gpnmb expression at six or eight days after single injection of CCl4. Values are mean ± SEM (n = 4). * P < 0.05 (Mann-Whitney U test). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/26599547), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Osteoactivin/GPNMB by Immunohistochemistry
Sequential changes in and localization of Gpnmb expression. Gpnmb expression is enhanced in the recovery phase (A) in whole liver as determined by Western blotting and (B) in isolated hepatic macrophages as determined by quantitative real-time polymerase chain reaction (n = 5 at each day). (C) Moreover, Gpnmb expression is observed immunohistochemically around injured lesions in a pattern similar to that in F4/80-positive macrophages, and Gpnmb-positive cells exhibit partial phagocytosis. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/26599547), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Osteoactivin/GPNMB by Immunohistochemistry
Characteristics of gpnmb-positive cells infiltrating liver tissue. In LMNCs isolated from injured liver, (A) more than 90% of hepatic macrophages positive for F4/80 are also positive for CD68, whereas CD11b is expressed in approximately 10% of F4/80-positive cells. Gpnmb expression is detected in approximately 50% of CD68-positive cells. (B) Immunofluorescent double staining shows that some CD68-positive cells are also positive for Gpnmb (scale bar: upper, 100 μm; lower, 50 μ m). (C) Some Gpnmb-positive cells show phagocytosis of apoptotic cells (scale bar: left side, 100 μm; right side, 50 μm). (D) Phagocytic activity of CD68-positive cells is significantly higher than that of CD11b-positive cells. Additionally, in CD68-positive cells, phagocytic activity of Gpnmb-positive cells is significantly increased compared with that in Gpnmb-negative cells. Values are mean ± SEM (n = 3). * P < 0.05 (Mann-Whitney U test). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/26599547), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Osteoactivin/GPNMB by Western Blot
Sequential changes in and localization of Gpnmb expression. Gpnmb expression is enhanced in the recovery phase (A) in whole liver as determined by Western blotting and (B) in isolated hepatic macrophages as determined by quantitative real-time polymerase chain reaction (n = 5 at each day). (C) Moreover, Gpnmb expression is observed immunohistochemically around injured lesions in a pattern similar to that in F4/80-positive macrophages, and Gpnmb-positive cells exhibit partial phagocytosis. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/26599547), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Mouse Osteoactivin/GPNMB Antibody (297310)
Western Blot
Sample: Recombinant Mouse Osteoactivin/GPNMB Fc Chimera (Catalog # 2330-AC)
Formulation, Preparation, and Storage
Purification
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: Osteoactivin/GPNMB
References
- Bachner, D. et al. (2002) Gene Exp. Patterns 1:159.
- Shikano, S. et al. (2001) J. Biol. Chem. 276:8125.
- Owen, T.A. et al. (2003) Crit. Rev. Eukaryot. Gene Expr. 13:205.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional Osteoactivin/GPNMB Products
Product Documents for Mouse Osteoactivin/GPNMB Antibody (297310)
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Mouse Osteoactivin/GPNMB Antibody (297310)
For research use only
Related Research Areas
Customer Reviews for Mouse Osteoactivin/GPNMB Antibody (297310)
There are currently no reviews for this product. Be the first to review Mouse Osteoactivin/GPNMB Antibody (297310) and earn rewards!
Have you used Mouse Osteoactivin/GPNMB Antibody (297310)?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 for a review with an image
$10/€7/£6/$10CAN/¥1110 for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- Cellular Response to Hypoxia Protocols
- R&D Systems Quality Control Western Blot Protocol
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars